Alcoholic liver disease treating and preventing drug and composition thereof

A technology for alcoholic liver disease and a composition, which is applied in the field of medicine, can solve the problems that the pathological index evaluation system is slightly incomplete, and the therapeutic effect of fat-related diseases and liver diseases is not discussed, and achieves good popularization and application value. Medicinal effect

Inactive Publication Date: 2018-11-13
阎永平
View PDF22 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The patent only involves the application of preparing tumor drugs, and does not discuss the therapeutic effect of fat-related diseases and liver diseases
And there are factors such as the pathological index evaluation system is not complete

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alcoholic liver disease treating and preventing drug and composition thereof
  • Alcoholic liver disease treating and preventing drug and composition thereof
  • Alcoholic liver disease treating and preventing drug and composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Different doses of kaempferol were used to prevent and treat alcoholic liver disease caused by NIAAA model.

[0064] 1. Instruments and materials:

[0065] Main instruments: full-wavelength microplate reader (Thermo Company, USA).

[0066] Drugs and reagents: liquid feed (Lieber-DeCarli diet ad libitum) and liquid alcohol feed (Nantong Trophy Feed Technology Co., Ltd.); alcohol (Burdick&Jackson); kaempferol (≥98%, Chengdu Mansite Biotechnology Co., Ltd.) ; ALT, AST, TG detection kits (Nanjing Jiancheng Institute of Bioengineering); other reagents are of analytical grade.

[0067] 2. Experimental animals and dosing regimen:

[0068] C57BL / 6 mice, male, 8-9 weeks old, provided by the Experimental Animal Center of Guangzhou University of Traditional Chinese Medicine, were fed with control liquid feed or liquid alcohol feed according to different groups. Mice were fed a control liquid diet (Lieber-DeCarli diet adlibitum) for 5 days; they were acclimated to liquid diet. ...

Embodiment 2

[0088] β-sitosterol is used to prevent and treat alcoholic fatty liver caused by NIAAA model.

[0089] 1. Instruments and materials

[0090] β-sitosterol (≥98%, Chengdu Master Biological Technology Co., Ltd.); the rest are the same as in Example 1.

[0091] 2. Experimental animals and dosing regimen

[0092] The mice were randomly divided into 3 groups, 6 in each group, and the groups were blank control liquid feed group, alcohol modeling group, and alcohol modeling co-administration group. Wherein the alcohol modeling co-administration group contains β-sitosterol (10 / 20 / 30mg / kg); the rest are the same as in Example 1.

[0093] Liver tissue and serum chemical detection, mathematical statistics are the same as in Example 1.

[0094] 3. Experimental results

[0095] General situation: Compared with the control liquid feed group, the liver volume, rough surface and color change of the alcohol modeling group can be clearly observed by the naked eye after dissection. After syn...

Embodiment 3

[0109] Tanshinone I is used to prevent and treat alcoholic fatty liver caused by NIAAA model.

[0110] 1. Instruments and materials

[0111] Tanshinone I (≥98%, Chengdu Master Biological Technology Co., Ltd.); the rest are the same as in Example 1.

[0112] 2. Experimental animals and dosing regimen

[0113] Mice are divided into 5 groups at random, 6 in every group, and group is blank control liquid feed group, alcohol modeling group, alcohol modeling cooperating administration group: wherein the dosage of Tanshinone I is: 15mg / kg, 30mg / kg, 60mg / kg, all the other are with embodiment 1.

[0114] Liver tissue and serum chemical detection, data statistics are the same as in Example 1.

[0115] Experimental results:

[0116] Compared with the control liquid feed group, the larger liver volume, rough surface, and color change of the alcohol modeling group could be clearly observed by the naked eye after dissection. After co-administration of the above doses, the above patholo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a drug composition composed of kaempferol, beta-sitosterol and/or tanshinone I and application thereof to preparing alcoholic liver disease treating and preventing drugs. The drug composition is composed of 3-55% of the kaempferol, 10-60% of the beta-sitosterol and 20-80% of the tanshinone I, and an independently applicable drug is composed of 0.5-70% of the kaempferol, 0.03-70% of the beta-sitosterol and 1.5-99% of the tanshinone I. implementing mice alcoholic liver injury models proves the therapeutic effects of the kaempferol, the beta-sitosterol, the tanshinone I and the drug composition on alcoholic liver diseases. Both the drug and the drug composition can effectively reduce liver lesions, particularly, significantly reduce hepatomegaly and weight increment, significantly decrease activity of serum transaminase and intrahepatic triglyceride content, and significantly improve tissue fat accumulation and inflammatory infiltration. The drugs can all prevent and treat alcoholic liver diseases, and also, can independently serve as drugs and be applied to developing corresponding drugs and healthcare products.

Description

technical field [0001] The invention belongs to the field of medicine. More specifically, it relates to the application of kaempferol, β-sitosterol, tanshinone I and any pharmaceutical composition thereof in the preparation of drugs and health care products for the prevention and treatment of alcoholic liver disease. Background technique [0002] Alcoholic liver disease (ALD) is liver damage caused by long-term heavy drinking, including alcoholic fatty liver (Alcoholic fatty liver, AFL), alcoholic hepatitis (Alcoholichepatitis, AH), alcoholic liver fibrosis (Alcoholic liver fibrosis) Fibrosis, AF) and alcoholic cirrhosis (Alcoholiccirrhosis, AC); the three are often mixed. Clinically, 80% to 90% of the causes of liver cirrhosis are caused by alcohol consumption. More than 20,000 people in the United States die each year from alcoholic cirrhosis. In recent years, the trend of alcohol consumption in my country has increased sharply with the improvement of life, and the inci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61K31/343A61K31/352A61P1/16
CPCA61K31/343A61K31/352A61K31/575A61K2300/00
Inventor 胡冰芳
Owner 阎永平
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap